Caring Brands Announces Exclusive Global License to Manufacture and Market Emesyl

Rhea-AI Summary

Caring Brands (Nasdaq: CABR) entered an exclusive worldwide license with Itonis to manufacture, market, and distribute Emesyl, an over-the-counter nausea relief product, effective Jan 5, 2026.

Under the agreement Caring Brands will assume global manufacturing, marketing, sales strategy, and distribution while Itonis will supply technical, formulation, historical sales, and IP information. The deal includes a royalty on future net sales and potential equity earn‑outs tied to revenue milestones. The release cites a QY Research market projection of USD 6.23 billion for nausea treatments in 2025. Caring Brands said it will provide further updates on timelines, manufacturing progress, and commercial rollout as initiatives advance.

Key Figures

Global nausea market USD 6.23 billion Projected 2025 market size for nausea treatments (QY Research)

Market Reality Check

$1.14 Last Close

Volume Volume 91,057 vs 20-day average 178,966 indicates activity remains below typical levels. low

Technical Price at 1 is trading below the 200-day MA of 1.09.

Peers on Argus

No peers with momentum or same-day headlines were detected, suggesting CABR’s 16.58% move reflects company-specific news around the Emesyl license.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 14	Uplisting and offering	Neutral	-28.1%	Closing of $4M underwritten offering linked to Nasdaq uplisting.
Nov 12	Offering pricing	Neutral	-54.4%	Pricing of $4M public offering and approval to list on Nasdaq.

Pattern Detected

Recent history shows sharp negative reactions to capital-raising/uplisting news, contrasting with the positive response to today’s commercial licensing announcement.

Recent Company History

In mid-November 2025, Caring Brands executed a Nasdaq uplisting with an underwritten public offering of 1,000,000 shares at $4.00, targeting about $4,000,000 in gross proceeds. Pricing and closing announcements on Nov 12 and Nov 14 coincided with steep one-day declines of -54.43% and -28.06%, respectively, suggesting investors were sensitive to dilution and capital structure changes. By contrast, today’s Emesyl licensing deal expands the OTC product portfolio, marking a shift from balance-sheet events toward commercial growth initiatives.

Market Pulse Summary

The stock surged +24.0% in the session following this news. A strong positive reaction aligns with the market’s shift from prior dilution-focused events to a commercial growth story. The Emesyl license grants global rights to an OTC nausea product within a market projected at USD 6.23 billion by 2025. Past offerings in November 2025 saw sharp drops of -54.43% and -28.06%, so investors may watch whether execution on manufacturing and rollout sustains enthusiasm absent new financing pressure.

Key Terms

over-the-counter (otc) financial

"Itonis’s over-the-counter (OTC) nausea relief product."

Over-the-counter (OTC) describes stocks and other securities traded directly between buyers and sellers outside formal exchanges, using brokers, dealers, or electronic networks. For investors it matters because OTC trading often means lower transparency, fewer rules and thinner trading volume—like buying at a small flea market instead of a big supermarket—so prices can swing more and the risk of not being able to sell quickly is higher.

intellectual property regulatory

"historical sales information, and intellectual property details to support"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

royalty structure financial

"The agreement includes a royalty structure based on future net sales"

A royalty structure is the set of rules that determines how and when the owner of an asset—like a patent, trademark, mineral right, or a drug formula—gets paid when others use or sell it. Think of it as a commission or rent agreement that specifies payment rates (fixed fee, percent of sales, or per-unit amounts), timing, and duration; it matters to investors because it shapes future cash flow, profit margins, risk sharing and the valuation of any business that relies on or pays these royalties.

equity financial

"potential for Caring Brands to earn equity in Itonis tied to revenue"

Equity is an ownership stake in a company, usually represented by shares, that gives the owner a claim on the company’s profits and on its assets after debts are paid. For investors, equity matters because its value rises and falls with the company’s performance, determines potential dividend income and voting influence, and represents both the upside (growth) and the risk (loss) of owning a slice of the business, like owning a piece of a pie whose size can change.

AI-generated analysis. Not financial advice.

Jupiter, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) today announced that it has entered into an exclusive worldwide license agreement with Itonis Inc. to manufacture, market, and distribute Emesyl, Itonis’s over-the-counter (OTC) nausea relief product. The agreement provides Caring Brands with full rights to commercialize Emesyl and to oversee all manufacturing activities associated with the product.

Under the terms of the agreement, Caring Brands will assume responsibility for product manufacturing, marketing, sales strategy, and global distribution. Itonis will provide technical information, product formulation data, historical sales information, and intellectual property details to support Caring Brands’ commercial launch and ongoing development efforts.

According to QY Research, the global market for nausea treatment and related therapies is projected to exceed USD 6.23 billion in 2025, underscoring the broader commercial context for the Emesyl license.

Glynn Wilson, CEO of Caring Brands Inc., said, “Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence. This agreement aligns perfectly with our long‑term strategy for OTC products, and we are excited to share more about our upcoming plans in the months ahead.”

The agreement includes a royalty structure based on future net sales, along with the potential for Caring Brands to earn equity in Itonis tied to revenue milestones. Caring Brands expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as these initiatives advance.

About Caring Brands

Caring Brands Inc. has a growing portfolio of unique, patented, and clinically validated products for skin and hair growth. The Company intends to launch a total of 5 products over the next 2 years in addition to in-licensing additional products. Management has a successful track record of strategic acquisitions, rapid product development, IP development and product licensing. Revenues from the sales of Hair Enzyme Booster for the treatment of hair loss, and Photocil for the treatment of psoriasis and vitiligo, are currently being generated by direct sales in the US and licensees in India. Additional product opportunities include CB-101 for the treatment of eczema, NoStingz, a sunscreen that prevents jellyfish stings.

Contact:

Brian S John
Chief Investment Officer
(561) 896-7616

Forward-Looking Statements

This communication contains forward-looking statements regarding Caring Brands, Inc., including, the anticipated timing of studies and the results and benefits thereof. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are based on each of the Company’s current plans, objectives, estimates, expectations, and intentions and inherently involve significant risks and uncertainties, many of which are beyond our control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties and other risks and uncertainties affecting Caring Brands, Inc.. Moreover, other risks and uncertainties of which the combined company is not currently aware may also affect each of the companies’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and reflect the views stated therein with respect to future events at such dates, even if they are subsequently made available by Caring Brands, Inc. on its website or otherwise. Caring Brands, Inc. undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

FAQ

What did Caring Brands announce about Emesyl on Jan 5, 2026 (CABR)?

Caring Brands announced an exclusive worldwide license from Itonis to manufacture, market, and distribute Emesyl, effective Jan 5, 2026.

How will the Emesyl license affect CABR’s responsibilities?

Caring Brands will assume product manufacturing, marketing, sales strategy, and global distribution for Emesyl.

Does the Emesyl agreement include payments or equity for Itonis in the CABR deal?

Yes; the agreement includes a royalty structure on future net sales and potential equity for Itonis tied to revenue milestones.

What commercial context did CABR cite for the Emesyl license (market size)?

The announcement cited a QY Research projection of a global nausea treatment market exceeding USD 6.23 billion in 2025.

Will CABR provide timelines for Emesyl manufacturing and launch?

Caring Brands said it expects to provide further updates on product timelines, manufacturing progress, and commercial rollout as initiatives advance.